Press Releases

Date Title and Summary Additional Formats
Toggle Summary FDA Lifts Clinical Hold on Concert Pharmaceuticals Clinical Trial with CTP-543
Concert to Resume Enrollment in Modified Phase 2a Trial for Alopecia Areata LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ:CNCE) today announced that the U.S. Food and Drug Administration (FDA) has notified the Company that it has lifted the clinical hold on Concert's
View HTML
Toggle Summary Concert Pharmaceuticals Announces $30 Million Venture Debt Financing from Hercules Capital
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has entered into a $30.0 million venture debt financing agreement with Hercules Capital, Inc. "This non-dilutive financing further extends our existing cash runway.
View HTML
Toggle Summary Concert Pharmaceuticals to Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will present a corporate overview at the Jefferies 2017 Global Healthcare Conference on June 6, 2017 , at 10:30 a.m. ET in New York, NY . In addition, the Company will participate on the
View HTML
Toggle Summary Concert Pharmaceuticals Announces Departure of Chief Financial Officer, Ryan Daws
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that Ryan Daws , Chief Financial Officer, will be leaving the company in early June 2017 to return to investment banking. He will be joining Baird as Managing Director in the firm's Life Sciences and
View HTML
Toggle Summary Concert Pharmaceuticals Announces Shareholder Approval of CTP-656 Asset Purchase Agreement with Vertex Pharmaceuticals
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that in connection with its annual shareholder meeting, Concert shareholders voted to approve the asset purchase agreement under which Vertex Pharmaceuticals, Inc.
View HTML
Toggle Summary Concert Pharmaceuticals Receives Second Request from FTC Under HSR Act
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received a request for additional information ("Second Request") from the United States Federal Trade Commission (FTC) in connection with the pending acquisition of CTP-656 and other assets
View HTML
Toggle Summary Concert Pharmaceuticals Announces Clinical Hold on CTP-543 Phase 2a Trial
-- FDA Requested Review of Recently Completed Non-Clinical Studies -- -- FDA Did Not Cite a Safety Concern -- LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it has received notice from the U.S. Food and Drug Administration (FDA) that its
View HTML
Toggle Summary Concert Pharmaceuticals Reports First Quarter 2017 Financial Results
Conference Call Scheduled Today at 8:30 a.m. EDT LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today reported financial results for the first quarter of 2017. "We expect to significantly strengthen our cash position in 2017 through the asset purchase agreement
View HTML
Toggle Summary Concert Pharmaceuticals Initiates CTP-543 Phase 2 Trial in Alopecia Areata
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced the initiation of a Phase 2a clinical trial evaluating CTP-543 for the treatment of moderate-to-severe alopecia areata, an autoimmune disorder in which the immune system attacks hair follicles,
View HTML
Toggle Summary Concert Pharmaceuticals to Report First Quarter 2017 Financial Results on May 2, 2017, and Present at Upcoming Investor Conferences
LEXINGTON, Mass. --(BUSINESS WIRE)-- Concert Pharmaceuticals, Inc. (NASDAQ: CNCE) today announced that it will report its first quarter 2017 financial results on Tuesday, May 2, 2017 , before the U.S. financial markets open. The Company will host a conference call and webcast at 8:30 a.m.
View HTML